Identifying Maternal Conditions Leading to Gabapentinoid Prescriptions in Pregnancy Using Electronic Health Records from Six European Countries: A Contribution from the IMI ConcePTION Project
Our study provides valuable insights into gabapentinoid use during pregnancy, with anxiety being the most common condition among pregnant women with gabapentinoid prescriptions in Finland, Italy, Spain, and Wales, whereas neuropathic pain predominated in France and Norway. Moreover, we found that between 3 and 23% of these pregnancies were associated with substance abuse, underscoring the need for careful prescribing of commonly abused medicines. The proposed methods for detecting maternal conditions leading to prescribing will facilitate accurate assessment of medication use and safety during pregnancy, whilst addressing confounding by indication.
Authors
- Anna‐Belle Beau (ORCID: https://orcid.org/0000-0003-4631-100X)
- Laura García‐Villodre (ORCID: https://orcid.org/0000-0001-9094-7107)
- Aurora Puccini
- Olga Paoletti (ORCID: https://orcid.org/0009-0009-0434-8745)
- Laia Barrachina‐Bonet (ORCID: https://orcid.org/0000-0002-5272-265X)
- Joan K. Morris (ORCID: https://orcid.org/0000-0002-7164-612X)
- Clara Cavero‐Carbonell (ORCID: https://orcid.org/0000-0002-4858-6456)
- Mika Gissler (ORCID: https://orcid.org/0000-0001-8254-7525)
- Marco Manfrini (ORCID: https://orcid.org/0000-0003-3154-9269)
- Vera Ruth Mitter (ORCID: https://orcid.org/0000-0002-1483-5020)
- Anja Geldhof (ORCID: https://orcid.org/0000-0002-6476-5526)
- Justine Bénevent (ORCID: https://orcid.org/0000-0001-9048-5336)
- Maarit K. Leinonen (ORCID: https://orcid.org/0000-0002-7631-4749)
- Xavier Moisset (ORCID: https://orcid.org/0000-0002-8799-0750)
- Rosa Gini (ORCID: https://orcid.org/0000-0002-6250-877X)
- Sue Jordan (ORCID: https://orcid.org/0000-0002-5691-2987)
- Elisa Ballardini (ORCID: https://orcid.org/0000-0002-8813-1835)
- Visa Martikainen
- Christine Damase‐Michel
- Jingping Mo
- Amanda J. Neville
- Hedvig Nordeng
- Marie Beslay (ORCID: https://orcid.org/0000-0002-5153-1747)
- Alex Coldea
Institutions
- Agenzia Regionale per la Protezione Ambientale del Piemonte (IT)
- Bern University of Applied Sciences (CH)
- Université Toulouse III - Paul Sabatier (FR)
- Inserm (FR)
- St George's, University of London (GB)
- Université Fédérale de Toulouse Midi-Pyrénées (FR)
- Pfizer (United States) (US)
- University of Oslo (NO)
- University of Ferrara (IT)
- Université Paris Cité (FR)
- Swansea University (GB)
- Finnish Institute for Health and Welfare (FI)
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (ES)
- University of Clermont Auvergne (FR)
- Physiopathologie et pharmacologie de la douleur et de la migraine (FR)
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
- Clermont Université (FR)
- Sciences, Philosophie, Histoire (FR)
- Janssen (Netherlands) (NL)
- Agenzia Regionale di Sanità della Toscana (IT)
- Regione Emilia-Romagna
- City St George's, University of London (GB)
Publication Details
- Journal
- Drug Safety
- Published
- 2025-06-13
- DOI
- https://doi.org/10.1007/s40264-025-01565-2
- Citations
- 1
- Primary Topic
- Pharmacological Effects and Toxicity Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.49
Funders
- Swansea University
- Université de Toulouse
- Universitetet i Oslo
- Innovative Medicines Initiative
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana